205 related articles for article (PubMed ID: 18418594)
41. 18F-FDG PET/CT and primary hepatic MALT: a case series.
Albano D; Giubbini R; Bertagna F
Abdom Radiol (NY); 2016 Oct; 41(10):1956-9. PubMed ID: 27259334
[TBL] [Abstract][Full Text] [Related]
42. 18F-FDG PET/CT for staging and response assessment of primary parotid MALT lymphoma with multiple sites involvement: A case report.
Ren Y; Huang L; Han Y; Cui Z; Li J; Dong C; Liu J
Medicine (Baltimore); 2019 Feb; 98(5):e14270. PubMed ID: 30702589
[TBL] [Abstract][Full Text] [Related]
43. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
[TBL] [Abstract][Full Text] [Related]
44. 18F-FDG PET in malignant lymphoma: significance of positive findings.
Castellucci P; Zinzani P; Pourdehnad M; Alinari L; Nanni C; Farsad M; Battista G; Tani M; Stefoni V; Canini R; Monetti N; Rubello D; Alavi A; Franchi R; Fanti S
Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):749-56. PubMed ID: 15785956
[TBL] [Abstract][Full Text] [Related]
45. Fluorodeoxyglucose positron emission tomography (FDG-PET) and PET/computed tomography imaging characteristics of thyroid lymphoma and their potential clinical utility.
Basu S; Li G; Bural G; Alavi A
Acta Radiol; 2009 Mar; 50(2):201-4. PubMed ID: 19089692
[TBL] [Abstract][Full Text] [Related]
46. Testicular fluorine-18 fludeoxyglucose uptake on positron emission tomography CT in patients with lymphoma: clinical significance and management impact.
Sidhu P; Lin P; Son H; Rosenfeld D; Lin M
Br J Radiol; 2014 Dec; 87(1044):20140472. PubMed ID: 25333503
[TBL] [Abstract][Full Text] [Related]
47. Physiologic thymic uptake of 18F-FDG in children and young adults: a PET/CT evaluation of incidence, patterns, and relationship to treatment.
Jerushalmi J; Frenkel A; Bar-Shalom R; Khoury J; Israel O
J Nucl Med; 2009 Jun; 50(6):849-53. PubMed ID: 19443604
[TBL] [Abstract][Full Text] [Related]
48. Primary gastric lymphoma: utility of 18F-fluorodeoxyglucose positron emission tomography-computed tomography for detecting relapse after treatment.
Sharma P; Suman SK; Singh H; Sharma A; Bal C; Malhotra A; Kumar R
Leuk Lymphoma; 2013 May; 54(5):951-8. PubMed ID: 23043310
[TBL] [Abstract][Full Text] [Related]
49. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma.
Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
Am J Hematol; 2014 Jul; 89(7):726-31. PubMed ID: 24711255
[TBL] [Abstract][Full Text] [Related]
50. 18F-Fluoro-deoxy-glucose positron emission tomography in lymphoma of mucosa-associated lymphoid tissue: histology makes the difference.
Hoffmann M; Wöhrer S; Becherer A; Chott A; Streubel B; Kletter K; Raderer M
Ann Oncol; 2006 Dec; 17(12):1761-5. PubMed ID: 16980600
[TBL] [Abstract][Full Text] [Related]
51. The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients.
Allen-Auerbach M; de Vos S; Czernin J
Radiol Clin North Am; 2008 Mar; 46(2):199-211, vii. PubMed ID: 18619376
[TBL] [Abstract][Full Text] [Related]
52. Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 Patients.
Mayerhoefer ME; Karanikas G; Kletter K; Kiesewetter B; Weber M; Rausch I; Pones M; Simonitsch-Klupp I; Müllauer L; Dolak W; Lukas J; Raderer M
Clin Nucl Med; 2016 Nov; 41(11):837-843. PubMed ID: 27648705
[TBL] [Abstract][Full Text] [Related]
53. 18F-FLT PET/CT imaging is not competent for the pretreatment evaluation of metastatic gastric cancer: a comparison with 18F-FDG PET/CT imaging.
Zhou M; Wang C; Hu S; Zhang Y; Yao Z; Li J; Guo W; Zhang Y
Nucl Med Commun; 2013 Jul; 34(7):694-700. PubMed ID: 23604223
[TBL] [Abstract][Full Text] [Related]
54. Genetic status determines
Tiwari A; Shah N; Sarathi V; Malhotra G; Bakshi G; Prakash G; Khadilkar K; Pandit R; Lila A; Bandgar T
J Med Imaging Radiat Oncol; 2017 Dec; 61(6):745-752. PubMed ID: 28585398
[TBL] [Abstract][Full Text] [Related]
55. Role of 18F-FDG-PET/CT in the management of marginal zone B cell lymphoma.
Carrillo-Cruz E; Marín-Oyaga VA; de la Cruz Vicente F; Borrego-Dorado I; Ruiz Mercado M; Acevedo Báñez I; Solé Rodríguez M; Fernández López R; Pérez Vega H; Calderón-Cabrera C; Espigado Tocino I; Pérez-Simón JA; Vázquez-Albertino R
Hematol Oncol; 2015 Dec; 33(4):151-8. PubMed ID: 25407794
[TBL] [Abstract][Full Text] [Related]
56. Differentiation of sarcoidosis-lymphoma syndrome lesions: a case report on the use of two different positron emission tomography tracers.
Yudistiro R; Arisaka Y; Tokue A; Nakajima T
BMC Med Imaging; 2016 Jan; 16():1. PubMed ID: 26746426
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of decreased uptake of 18F-fluorodeoxyglucose in the cerebral cortex of patients with intracranial non-Hodgkin's lymphoma lesions through PET/CT.
Zhang Q; Tian T; Wang L; Qiu H; Li D
Biomed Pharmacother; 2016 Dec; 84():1331-1336. PubMed ID: 27810790
[TBL] [Abstract][Full Text] [Related]
58. Characterization of T-cell lymphomas by FDG PET/CT.
Feeney J; Horwitz S; Gönen M; Schöder H
AJR Am J Roentgenol; 2010 Aug; 195(2):333-40. PubMed ID: 20651187
[TBL] [Abstract][Full Text] [Related]
59. FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease.
Paes FM; Kalkanis DG; Sideras PA; Serafini AN
Radiographics; 2010 Jan; 30(1):269-91. PubMed ID: 20083598
[TBL] [Abstract][Full Text] [Related]
60. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma.
Hoffmann M; Kletter K; Becherer A; Jäger U; Chott A; Raderer M
Oncology; 2003; 64(4):336-40. PubMed ID: 12759529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
